Inclusion Criteria:

- Inpatient greater than or equal to (>=) 18 years of age

- Pathologically proven squamous cell carcinoma arising in the oropharynx, hypopharynx
or larynx

- Stage III or IV disease with an expected survival of at least 12 months

- Medically suitable to withstand a course of concomitant boost RT

- Presence of at least 1 bi-dimensionally measurable lesion identified either by
computed tomography (CT) scan or magnetic resonance imaging (MRI) according to
modified World Health Organization (WHO) criteria

- Karnofsky Performance Status (KPS) >=80 at trial entry

- Neutrophils >=1.5*10^9/Liter (L), platelet count >= 100*10^9/L, hemoglobin >= 90
gram/liter (g/L)

- Total bilirubin less than or equal to (<=) 2*upper limit of normal (ULN); aspartate
aminotransferase (AST) and alanine aminotransferase (ALT) <= 3*ULN

- Serum creatinine <=133 micromole/liter (mcmol/L)

- Serum calcium within normal range

- Effective contraception if procreative potential exists (applicable to both male and
female subjects)

- Chinese with Chinese citizenship

- Signed written informed consent

Exclusion Criteria:

- Evidence of distant metastatic disease

- Squamous cell carcinoma arising in the nasopharynx or oral cavity

- Receipt of prior systemic chemotherapy within the last 3 years

- Previous surgery for the tumor under study other than biopsy

- Receipt of prior RT to the head and neck

- Currently receiving RT as part of a postoperative regimen following primary surgical
resection

- Planned neck dissection after trial RT

- Active infection (infection requiring IV antibiotics), including active tuberculosis,
or known and declared human immunodeficiency virus (HIV)

- Uncontrolled diabetes mellitus, pulmonary fibrosis, acute pulmonary disorder,
interstitial pneumonia, cardiac failure or liver failure

- Uncontrolled hypertension defined as systolic blood pressure >=180 millimeter of
mercury (mmHg) and/or diastolic blood pressure >=130 mmHg under resting conditions

- Pregnancy (absence to be confirmed by serum beta human chorionic gonadotrophin
[beta-HCG] test) or breastfeeding

- Concomitant chronic systemic immune therapy or hormonal therapy as cancer therapy

- Other concomitant anticancer therapies

- Documented or symptomatic brain or leptomeningeal metastasis

- Clinically relevant coronary artery disease or history of myocardial infarction in
the last 12 months or high risk of uncontrolled arrhythmia or uncontrolled cardiac
insufficiency

- Previous treatment with monoclonal antibody therapy, other signal transduction
inhibitors or epidermal growth factor receptor (EGFR) targeting therapy

- Evidence of previous other malignancy within the last 5 years

- Intake of any investigational medication within 30 days before trial entry

- Other protocol-defined exclusion criteria may apply